At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 99 enrolled
Drug / intervention
Galantaminedrug
Likely dose
Galantamine 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
In Brief
A Phase 4 clinical trial evaluating Galantamine for Alzheimer's Disease. Completed, enrolled 99 participants.
Detailed Summary
This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with Alzheimer's dementia and performing an attention test on baseline, week 4 and 12.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
Primary CompletionFeb 2009
First PostedJan 2010
TodayJul 2026
First PostedJan 22, 2010
Enrollment StartOct 1, 2006
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.4 years ago
Interventions
Galantaminedrug
Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.